Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | AXL Y821F |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| AXL Y821F | head and neck squamous cell carcinoma | sensitive | Cetuximab | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Erbitux (cetuximab) treatment inhibited proliferation of head and neck squamous cell carcinoma cells expressing AXL Y821F in culture, and delayed tumor growth in a cell line xenograft model (PMID: 32439698). | 32439698 | |
| AXL Y821F | head and neck squamous cell carcinoma | no benefit | Bemcentinib + Cetuximab | Preclinical - Cell culture | Actionable | In a preclinical study, combining Bemcentinib (BGB-324) with Erbitux (cetuximab) treatment inhibited proliferation of head and neck squamous cell carcinoma cells expressing AXL Y821F, but did not enhance inhibition compared to cells treated with Erbitux (cetuximab) alone in culture (PMID: 32439698). | 32439698 |